Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 3 Outcomes of CRE colonized patients compared to controls

From: Clinical significance and burden of carbapenem-resistant Enterobacterales (CRE) colonization acquisition in hospitalized patients

Outcome

CRE carriers (n = 340)

Non-colonized patients (n = 679)

Univariate OR (95% CI)

P value

PS weighted OR (95% CI)

P value

1-year mortality

138 (40.6)

250 (36.8)

1.17 (0.90–1.53)

0.243

0.98 (0.64–1.50)

0.936

30-day mortality

65 (19.1)

122 (18.0)

1.08 (0.77–1.51)

0.655

0.82 (0.52–1.53)

0.678

Length of stay in 1 year

18 [14–23]

7 [4–9]

    

1-year survivors

(n = 631)

18 [5–40]

7 [2–17]

2.05 (1.73–2.44)

 < 0.001*

1.52 (1.10–2.10)

0.011*

1-year non-

survivors (n = 388)

15 [6–36]

11 [4–31]

1.19 (0.97–1.48)

0.102

0.98 (0.66–1.46)

0.920

Any clinical infection

139 (40.9)

169 (24.6)

2.09 (1.58–2.75)

 < 0.001*

1.65 (1.06–2.56)

0.025*

Any BSI

60 (17.6)

56 (8.3)

2.38 (1.61–3.51)

 < 0.001*

1.98 (1.07–3.68)

0.030*

Enterobacterales BSI

40 (11.8)

36 (5.3)

2.37 (1.48–3.80)

 < 0.001*

2.02 (0.95–4.30)

0.069

CRE BSI**

14 (4.1)

0 (0)

  

CRE UTI**

13 (3.8)

0 (0)

    

CRE RTI**

7 (2.1)

0 (0)

    
  1. BSI bloodstream infection, UTI urinary tract infection, RTI respiratory tract infection
  2. *Statistically significant, **A CRE colonized patient might have had a CRE infection in multiple sites during follow-up